Gpx4 inhibitors, pharmaceutical compositions thereof, and their use for treating gpx4-mediated diseases
US-2024246901-A1 · Jul 25, 2024 · US
Benzamide compounds and related methods of use
US9533947B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9533947-B2 |
| Application number | US-201414292087-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 30, 2014 |
| Priority date | Dec 21, 2012 |
| Publication date | Jan 3, 2017 |
| Grant date | Jan 3, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.
First claim
Opening claim text (preview).
We claim: 1. A compound of a formula wherein R 1 is selected from phenyl, benzyl and heteroaryl moieties; each of E 1 and E 2 is independently selected from CH and N; and wherein each of R 1 and R 2 is optionally substituted with 1-5 substituents independently selected from but not limited to halo, cyano, nitro, hydroxy, amino, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, alkoxy, alkenyl, haloalkyl, aminoalkyl, hydroxyalkyl, alkylsulfonyl, alkylsulfinyl, haloalkylsulfonyl, haloalkylsulfinyl, alkylamido, alkylsulfonamido, alkylthio, alkylcarbonyl, alkoxycarbonyl and combinations of such substituents; each of R 3 and R 4 is independently selected from said substituents and combinations thereof; and each of n and m is an integer independently selected from 0-4, providing where R 1 is a benzothiazolyl moiety, E 1 and E 2 are CH, n is 1 and m is 0, R 3 is not a phenyl substituent at E 2 , and salts of said compounds. 2. The compound of claim 1 wherein m is 1-2. 3. The compound of claim 2 wherein R 1 is selected from phenyl and mono- and disubstituted phenyl moieties. 4. The compound of claim 3 wherein E 2 is CH, and E 1 is selected from CH and N. 5. The compound of claim 3 wherein n is 0.
Assignees
Inventors
Classifications
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
- C07C311/16Primary
having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Amides; Imides · CPC title
in position 3 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9533947B2 cover?
- Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.
- Who is the assignee on this patent?
- Univ Northwestern, Massachusetts Gen Hospital
- What technology area does this patent fall under?
- Primary CPC classification C07C311/16. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).